The Daily Fuckup

The Federal Trade Commission and seven states have asked a federal judge to hold Martin Shkreli in contempt, escalating a long-running fight over whether a lifetime ban from the pharmaceutical industry can actually be enforced against someone who still seems determined to stay in the orbit of drug finance and drug commentary. In a filing made Oct. 15, regulators said Shkreli has continued to violate a court order that was meant to keep him out of the industry after his earlier misconduct made him one of the most notorious figures in modern pharmaceutical politics. The government is not reopening the original scandal so much as arguing that the punishment attached to it still matters, and that Shkreli has treated it like optional advice. According to the FTC, his post-prison behavior has included publicly trading in drug-company stocks and speaking often about pharmaceutical businesses, conduct the agency says runs directly against the terms and purpose of the injunction. The contempt motion is therefore less a new chapter in the old case than a test of whether a ban can function when the person it restrains remains visible, vocal, and financially interested in the same sector.

That matters because contempt is not a symbolic label. It is one of the court system’s sharper tools, a way of saying that a prior order was not a request, suggestion, or moral lecture but a binding command that carries consequences if ignored. The FTC’s theory is straightforward: if a court prohibits someone from participating in an industry, that person should not be able to keep circling it through public commentary, market activity, or other conduct that effectively preserves influence over the same field. Regulators will likely argue that the point of the original injunction was not just to stop Shkreli from working in pharmaceuticals in a narrow formal sense, but to cut off the practical leverage that comes from being active in and around drug businesses. Shkreli, for his part, may try to frame his conduct as speech, observation, or general market activity rather than prohibited industry involvement, though the exact contours of that defense will be for the court to sort out. The practical question now is whether the judge sees the alleged conduct as clever evasion or as behavior that still falls within the line the court drew years ago. If the FTC succeeds, it would reinforce the idea that lifetime bans can be more than headline-friendly punishments. If it fails, the case could become another example of how difficult it is to make durable restrictions stick when the target understands how to operate just outside their edges.

There is also a larger enforcement story buried inside the procedural fight. Agencies like the FTC often rely on injunctions and consent orders as long-term tools, especially in cases involving conduct they view as dangerous, repeatable, or hard to reverse once it spreads. Those orders are supposed to outlast the initial burst of outrage that produced them, which is why contempt proceedings can matter even when they do not produce the same public drama as the original case. They are the mechanism that turns an old judgment into a living obligation. In this instance, the agency is signaling that it still expects the order against Shkreli to have teeth, not just historical significance. That is especially important in a political environment where regulators are regularly accused of either under-enforcing the rules they win in court or overreaching when they try to prove they are serious. A contempt motion is a relatively unglamorous filing, but it sends a pointed message: if the government wins a ban, it expects the ban to mean something in practice. The seven states joining the request suggest this is not just a federal vanity project, but a broader attempt to preserve the credibility of the underlying judgment. Whether the judge agrees may depend on how the alleged conduct is characterized, how explicit the prior order was, and how much room there is between speaking about an industry and participating in it.

For Shkreli, the filing is another reminder that the legal and reputational consequences of his earlier conduct have not faded just because prison time ended. He has long served as a kind of public shorthand for pharmaceutical excess, investor arrogance, and the kind of behavior that makes regulators and lawmakers eager to draw bright lines. The contempt request does not relitigate every detail that made him infamous, but it does keep him in the same judicial spotlight and raises the possibility of fresh sanctions if the court finds the government’s claims persuasive. For the FTC, the filing is as much about institutional authority as it is about one man. It is a chance to show that old orders can still be enforced when a defendant appears to treat them as dead letters, and that the agency is willing to spend resources making sure a court’s prohibition remains meaningful. The case also highlights a basic tension in modern regulation: the more visible and media-savvy a banned individual becomes, the easier it is to test the boundaries of an injunction without necessarily stepping into a neatly defined violation. That is why this motion will likely be watched not only for what it says about Shkreli, but for what it says about the durability of regulatory punishment itself. No matter how the judge rules, the immediate point is clear enough: the FTC is not treating the lifetime ban as a relic, and it is not especially interested in letting Shkreli act as though the line no longer exists.